Weight loss self injections: what the clinical evidence shows

What the trial data actually established

The case for licensed weight loss self injections rests on some of the largest obesity-medicine trials ever run. In the SURMOUNT-1 study (2,539 adults with obesity, no diabetes, followed for 72 weeks) tirzepatide produced an average body-weight reduction of around 20–21% at the 15 mg maintenance dose, as reported in the New England Journal of Medicine. For semaglutide (Wegovy), the STEP 1 trial reported an average of around 15% at 72 weeks in a similarly structured population. Both are substantial, clinically meaningful numbers, not approximations dressed up as certainty.

There is a misconception worth naming quietly: some people assume self injection means the medicine does the work while nothing else needs to change. The trials enrolled participants alongside a reduced-calorie diet and increased physical activity; the weight loss figures reflect that combined approach. The injection reduces appetite and slows the rate at which the stomach empties, which makes eating less feel considerably less effortful, but it works with lifestyle changes, not instead of them.

NICE, in its appraisal of tirzepatide (TA1026), accepted these findings as the basis for recommending the medicine, noting that indirect comparisons favour tirzepatide over semaglutide 2.4 mg in average weight lost. That recommendation is worth reading if you want to understand the evidence bar the UK regulator applied.

The practicalities of injecting yourself at home

Both Mounjaro and Wegovy are supplied as pre-filled pens, no drawing up of doses, no glass vials. You press the pen against the skin, press the button, and hold for the recommended count. Most people find the process far less daunting than they expected after the first injection.

Injection sites rotate between the abdomen, outer thigh and upper arm. Rotating between sites matters: using the same spot repeatedly can affect how the medicine is absorbed. The pens are stored in the fridge at 2–8°C; there is a limited window during which they can be kept at room temperature, the exact number of hours is stated in the Patient Information Leaflet that comes with your pen, and that is the figure to follow.

Used needles are sharps waste. A 1-litre sharps container is the right way to dispose of them safely at home, returned to a participating pharmacy when full. Changing the needle for each injection is standard practice, and more detail on injection technique and storage is available if you want it before you start.

Who these medicines are licensed for in the UK

Both tirzepatide and semaglutide carry UK marketing authorisations for weight management in adults. The licensed eligibility criteria are: a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition, such as high blood pressure, raised cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. For some ethnic backgrounds, the threshold is 2.5 kg/m² lower under UK guidance.

Meeting those figures is a starting point, not a guarantee. A prescriber assesses the whole picture: other medicines you take, your personal and family medical history, any contraindications. Women using oral contraceptives should know that tirzepatide, in particular, may reduce pill absorption during the first four weeks of treatment and for four weeks after each dose increase, so an additional non-oral method is recommended during those windows, as noted by NHS England's guidance on weight management injections. These medicines are not licensed for pregnancy, breastfeeding or those actively trying to conceive, and they are not licensed for under-18s.

For a broader look at the landscape of weight loss injections available in the UK, including how the two main options compare, that page covers the full picture. If you are weighing up your options, our page covering the three weight loss injections most commonly prescribed in the UK sets out how they differ in a way that is easy to follow. If cost is a factor in your thinking, an honest breakdown of what weight loss injection treatment costs privately is worth reading alongside this.

The NHS route versus a private prescription

NHS access to these medicines exists but is tightly phased. Tirzepatide became available through GP practices from April 2026 under a new GP contract, but only for people meeting specific BMI and comorbidity criteria that narrow considerably from the licensed eligibility above, currently, most NHS pathways require a BMI of 35 or above plus multiple qualifying conditions. Wegovy on the NHS requires referral into a specialist weight management service, where waiting lists are commonly long.

A private prescription through a GPhC-registered pharmacy is the route for people who meet the licensed criteria but not the current NHS criteria, or who would rather not wait. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally, your answers go to a clinician's desk, not into an automated queue. If your application is approved and your order is placed before 12pm Monday to Friday, treatment is dispatched the same day and arrives the next working day via tracked DPD, in plain packaging. Our page on what to expect when your weight loss injection arrives is a useful read before your first delivery.

If you have questions before starting, our FAQs cover the most common ones, and our clinical team is reachable seven days a week. When you're ready to take the next step, check your eligibility with a free consultation.